The Indian Drug Manufacturers' Association (idma) has moved the Bombay High Court challenging various issues laid down in the amendments to the 1972 Patent Rules. The government had, in early June, notified the amendments to the Patent Rules following the enactment of the Patents (Amendment) Act, 1999. The petition, it is believed, challenges various "objectionable' clauses laid down in the rules. The drug body claims that the amended rules go much beyond the TRIPS requirements and even supercede the basic Patents (Amendment) Act, 1999.